RenovaCare, Inc. Enters R&D Partnership with World Leading Charité
New York & Pittsburgh, PA – November 17, 2015
RenovaCare, Inc. (OTCQB: RCAR), today announced a partnership to validate the science behind its groundbreaking technology for treatments of wounds, burns and other skin defects. The company’s research partner is Berlin-Brandenburg Center for Regenerative Therapies (BCRT), a translational research center at Charité – Universitätsmedizin Berlin, one of the world’s largest university hospitals.
The BCRT focuses on enhancing endogenous regeneration by cells, biomaterials, and factors, which can be used to develop and implement innovative therapies and products. RenovaCare, Inc. is the developer of the patented CellMist™ and SkinGun™ technologies for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing.
"This collaboration with a globally-renowned institution is a huge step forward for RenovaCare as we set out to achieve third party validation of the science behind the promise of our CellMist™ and SkinGun™ technologies," said Thomas Bold, President and CEO of RenovaCare, Inc. "We are honored to be working with such committed researchers known for partnering with innovative, world-class companies whose mission is to make peoples’ lives better."
"We are very excited to be working with RenovaCare to advance the treatment of burns, and this project underscores the new treatments for severely burned patients and those with a myriad skin conditions," said Dr. Katrin Zeilinger, Project Leader for BCRT. "We plan to assess all aspects of the company’s technology as it is related to the tissue’s wound-healing function and the characteristics of the treated site."
The objective of today’s announced research partnership is to evaluate protocols, methods, and outcomes related to the use of the RenovaCare proprietary SkinGun™. This includes better understanding the ability of delicate stem cells to survive and grow after being gently sprayed through SkinGun™ on to targeted body sites. Survival of these cells is vital to wound healing and recovery.
According to RenovaCare engineers, the company’s proprietary SkinGun™ spray device is the world’s most advanced technology of its kind, using an ultra-gentle non-turbulent air stream to spray the cells onto wounds. This is a marked improvement over pump spray devices, which create high-pressure forces behind a narrow aperture, exposing fragile cells to thrashing that is more likely to cause damage. Scientists at BCRT will also study various additional features and behaviors related to skin stem cells and their ability to replicate and grow, for wound healing.